LIVN
LivaNova PLC
NASDAQ · Healthcare · Medical - Devices · GB
$81.92
+0.89%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.5B | 1.4B | 1.3B | 1.2B | 1.0B |
| Cost of Revenue | 468.3M | 448.2M | 382.6M | 382.3M | 314.6M |
| Gross Profit | 1.0B | 939.9M | 870.9M | 771.3M | 707.2M |
| Operating Expenses | |||||
| R&D Expense | 203.5M | 185.8M | 182.5M | 193.8M | 155.8M |
| SG&A Expense | 583.5M | 548.8M | 526.3M | 518.1M | 469.2M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 17.9M | 5.9M | 33.0M | 127.8M | 158.9M |
| Total Operating Expenses | 804.9M | 740.5M | 741.8M | 839.7M | 784.0M |
| Cost and Expenses | 1.3B | 1.2B | 1.1B | 1.2B | 1.1B |
| Operating Income (EBIT) | 198.3M | 199.4M | 129.1M | (68.5M) | (76.8M) |
| Non-Operating | |||||
| Interest Income | 13.9M | 19.0M | 30.1M | 22.0M | 4.7M |
| Interest Expense | 46.1M | 49.3M | 63.1M | 58.9M | 48.3M |
| Net Interest Income | (32.2M) | (30.3M) | (33.0M) | (36.8M) | (43.6M) |
| Other Non-Op Income/Expense | (91.6M) | (420.2M) | (40.7M) | (12.8M) | 1.6M |
| Non-Operating Income (excl Interest) | 45.5M | 370.9M | (22.3M) | (46.1M) | (49.9M) |
| EBT (Pre-Tax Income) | 106.7M | (220.8M) | 88.3M | (81.3M) | (75.2M) |
| Income Tax Expense | (82.0M) | 21.6M | 25.1M | (98.9M) | 11.1M |
| Bottom Line | |||||
| Net Income | 188.6M | (242.5M) | 63.2M | 17.5M | (86.2M) |
| Earnings from Cont. Ops | 188.6M | (242.5M) | 63.3M | 17.5M | (86.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 188.6M | (242.5M) | 63.2M | 17.5M | (86.2M) |
| Per Share | |||||
| Basic EPS | $3.45 | ($4.45) | $1.17 | $0.33 | ($1.61) |
| Diluted EPS | $3.39 | ($4.45) | $1.16 | $0.32 | ($1.61) |
| Revenue Per Share | $26.75 | $25.47 | $23.11 | $21.40 | $19.10 |
| Shares | |||||
| Basic Shares Outstanding | 55.0M | 54.5M | 54.2M | 53.9M | 53.5M |
| Diluted Shares Outstanding | 56.3M | 54.5M | 54.6M | 54.2M | 53.5M |
| Profitability Metrics | |||||
| EBITDA | 180.7M | (129.5M) | 202.5M | 38.5M | 30.9M |
| D&A | 27.9M | 42.0M | 51.1M | 60.9M | 57.8M |
| EBIT | 152.8M | (171.5M) | 151.4M | (22.4M) | (26.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026